Objectives: This study compared the tolerability of a Lyme disease vaccine administered intramuscularly at 0 and 1 months with that of a vaccine administered at 0, 1, and 2 months to determine (1) whether adding a third dose of vaccine 1 month after the second would affect the safety profile, and (2) whether a shortened vaccination schedule of 0, 1, and 2 months would provide an immune response similar to that obtained with vaccine administered at 0, 1, and 12 months.
Background: An efficacy trial of a Lyme disease vaccine had demonstrated safety and efficacy against definite (clinically manifested and laboratory-confirmed) Lyme disease after 3 doses at 0, 1, and 12 months and resulted in 90% of subjects having titers > or =1400 enzyme-linked immunosorbent assay units (EL.U)/mL (the proposed seroprotective level for 1 tick season).
Methods: This multicenter, open-label, prospective, randomized study assessed the safety and efficacy of different doses of a recombinant outer-surface protein A (OspA) vaccine in 956 volunteers aged 17 to 72 years from 3 Lyme disease-endemic sites. Blood samples were collected at months 0, 2, 3, 12, and 13 to assess total immunoglobulin-G anti-OspA titers.
Results: Most adverse events were transient and mild to moderate. The geometric mean antibody titer increased 2.8-fold from month 2 (1786 EL.U/mL to 4842 EL.U/mL), and approximately 90% of the volunteers had a titer > or =1400 and 99% had a titer > or =400 EL.U/mL (the mini- mum seroprotective level at any given time) after the third dose. An antibody kinetics model predicts that protection would last for a typical tick-transmission season.
Conclusions: In volunteers aged 17 to 72 years, 3 doses of vaccine administered in 2 months was well tolerated, more immunogenic than 2 doses, and provided a higher probability of protection before exposure or travel to Lyme disease-endemic areas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0149-2918(00)80035-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Climate-induced expansion of Lyme disease in east central Ohio.
Int J Environ Health Res
January 2025
School of Geosciences, University of South Florida, Tampa, FL, USA.
The geographical distribution of Lyme disease has been attributed to changes in Earth's climate and associated distribution of its vector, ticks of the genus . This study focuses on the impact of climatic and meteorological conditions on Lyme disease transmission in East Central Ohio, an emerging hotspot of cases. Using county-level data from 2001 to 2023, we analyzed the relationship between Lyme disease cases and temperature, precipitation, and the Southern Oscillation Index (SOI) using a distributed lag nonlinear model (DLNM).
View Article and Find Full Text PDFPositive feedback regulation between RpoS and BosR in the Lyme disease pathogen.
mBio
January 2025
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
In , the causative agent of Lyme disease, differential gene expression is primarily governed by the alternative sigma factor RpoS (σ). Understanding the regulation of RpoS is crucial for elucidating how is maintained throughout its enzootic cycle. Our recent studies have shown that the homolog of Fur/PerR repressor/activator BosR functions as an RNA-binding protein that controls the mRNA stability.
View Article and Find Full Text PDFCongeneric Rodents Differ in Immune Gene Expression: Implications for Host Competence for Tick-Borne Pathogens.
J Exp Zool A Ecol Integr Physiol
January 2025
Global Health and Interdisciplinary Disease Research Center and Center for Genomics, College of Public Health, Interdisciplinary Research Building (IDRB), Tampa, Florida, USA.
Mice in the genus Peromyscus are abundant and geographically widespread in North America, serving as reservoirs for zoonotic pathogens, including Borrelia burgdorferi (B. burgdorferi), the causative agent of Lyme disease, transmitted by Ixodes scapularis ticks. While the white-footed mouse (Peromyscus leucopus (P.
View Article and Find Full Text PDFLyme disease associated neurological and musculoskeletal symptoms: A systematic review and meta-analysis.
Brain Behav Immun Health
February 2025
University Center for Research and Development, Chandigarh University, Mohali, Punjab, India.
Background And Objective: Lyme disease, caused by , presents major health challenges worldwide, leading to serious neurological and musculoskeletal issues that impact patients' lives and healthcare systems. This systematic review and meta-analysis aim to determine the prevalence and link between Lyme disease and these complications, aiming to enhance clinical and public health approaches.
Methods: We systematically searched PubMed, EMBASE, and Web of Science up until April 01, 2024, to find studies reporting the prevalence and severity of neurological and musculoskeletal complications associated with Lyme disease.
Unveiling Lyme Neuroborreliosis in the Absence of Dermatological Symptoms.
Cureus
December 2024
Internal Medicine, Central Michigan University, Saginaw, USA.
Lyme neuroborreliosis can present with isolated neurological manifestations, posing diagnostic challenges, especially in the absence of hallmark dermatological symptoms like erythema migrans. This case highlights a patient with isolated cervical radiculopathy due to Lyme neuroborreliosis, presenting without systemic features such as fever, arthralgia, or rash. The diagnosis was confirmed through serological testing, with positive findings on the Western blot.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!